Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2

Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2—A Phase I Study

Published:2009-06-12 Issue:7 Volume:50 Page:1153-1160
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Andersson Håkan,Cederkrantz Elin,Bäck Tom,Divgi Chaitanya,Elgqvist Jörgen,Himmelman Jakob,Horvath György,Jacobsson Lars,Jensen Holger,Lindegren Sture,Palm Stig,Hultborn Ragnar

Publisher

Society of Nuclear Medicine

Subject

Radiology Nuclear Medicine and imaging

Reference35 articles.

1. Phase III Trial of Intraperitoneal Therapy With Yttrium-90–Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete Remission

2. The Curative and Palliative Potential of the Monoclonal Antibody MOv18 Labelled with211At in Nude Mice with Intraperitoneally growing Ovarian Cancer Xenografts - A Long-Term Study

Cited by 230 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transforming Cancer Treatment: The Evolving Landscape of Targeted α-Particle Therapy;Indian Cancer Awareness Journal;2024-07-29

2. Qualitative and quantitative imaging of alpha‐emitting radiopharmaceuticals;iRADIOLOGY;2024-06-25

3. The Different Strategies for the Radiolabeling of [211At]-Astatinated Radiopharmaceuticals;Pharmaceutics;2024-05-30

4. In vitro and in vivo evaluation of a tetrazine-conjugated poly-L-lysine effector molecule labeled with astatine-211;EJNMMI Radiopharmacy and Chemistry;2024-05-22

5. Behaviour, use and safety aspects of astatine-211 solvated in chloroform after dry distillation recovery;Scientific Reports;2024-04-27